IPN10200

Phase 3

Ipsen Biopharmaceuticals, Inc. (IPSEY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Aug '26

IPSEYPhase 3$15.0B

IPN10200 Phase 3 Est. Readout

IPN10200• Moderate to Severe Upper Facial Lines300

Aug 2026~ConfirmedSTALE

CT.gov

00%

Aug '26

IPSEYPhase 2$15.0B

IPN10200 Phase 2 Est. Readout

IPN10200• Moderate to Severe Upper Facial Lines240

Aug 2026~ConfirmedSTALE

CT.gov

00%

Aug '26

IPN.PAPhase 2$14.5B

IPN10200 Phase 2 Est. Readout

IPN10200• Moderate to Severe Upper Facial Lines727

Aug 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Moderate to Severe Upper Facial Lines

View Full Landscape

Drug Information

Target Indication

Moderate to Severe Upper Facial Lines

Clinical Trial

NCT04821089

Last updated: 3/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

IPSEY

Ipsen Biopharmaceuticals, Inc.

Healthcare•North America•NASDAQ

Related Pipeline

Triptorelin pamoate (embonate) saltPhase 3

Advanced Prostate Cancer

Lanreotide (Autogel formulation)Phase 3

Acromegaly

OdevixibatPhase 3

Biliary Atresia

Lanreotide Autogel®Phase 3

Acromegaly

ElafibranorPhase 3

Primary Biliary Cholangitis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts